Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Wyze Biotech Co., Ltd.
Zhongshan, Guangdong, Chinawyzebiotech.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Wyze Biotech is developing RJMty-19, an anti-CD19 CAR-T cell therapy currently in Phase 1 clinical trials in China for the treatment of autoimmune disorders like Systemic Lupus Erythematosus.
- Therapeutic areas
- Immunology
- Modalities
- CAR-T cell therapyDNT (Double Negative T) immune cell drugs
- Industry
- Biotech
02
Partnerships
Guangdong Ruishun Biotechnology Co., Ltd.
Beyond the preview
Go deeper on Wyze Biotech Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Wyze Biotech Co., Ltd..